MDMA + citalopram

MDMA + citalopram is a combination therapy under development for the treatment of post-traumatic stress disorder (PTSD). It consists of 3,4-methylenedioxymethamphetamine (MDMA), an entactogen and monoamine releasing agent, and citalopram, a selective serotonin reuptake inhibitor (SSRI). In this regimen, MDMA is administered first to produce its psychoactive effects. Citalopram is given several hours later to reduce negative after-effects such as mood disturbances ("Blue Mondays") and to mitigate MDMA-induced serotonergic neurotoxicity. The mechanism involves MDMA increasing synaptic serotonin by promoting its release via the serotonin transporter, while delayed administration of citalopram inhibits further serotonin reuptake and blocks neurotoxic effects without significantly diminishing the desired acute effects of MDMA. This approach aims to preserve therapeutic benefits while reducing adverse outcomes[1][2][3].

Brand names

celexactp

Other names

ecstasy (for mdma)midomafetamine (for mdma)